Gamma Secretase Complex is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The gamma-secretase complex is an intramembrane-cleaving aspartyl protease that performs regulated intramembrane proteolysis (RIP) of over 150 type I transmembrane protein substrates. Its most studied function is the cleavage of amyloid precursor protein (APP to generate amyloid-beta (Aβ peptides of varying lengths — the central event in the amyloid cascade hypothesis of Alzheimer's disease. Gamma-secretase also cleaves the Notch receptor, which is essential for cell fate determination during development and tissue homeostasis. Over 300 mutations in the catalytic subunit presenilin-1 (PSEN1 cause early-onset familial Alzheimer's Disease, making gamma-secretase one of the most genetically validated drug targets in neurodegeneration (De Strooper, 2003; Wolfe, 2019).
The gamma-secretase complex is a ~230 kDa heterotetramer composed of four essential transmembrane subunits, all of which are required for catalytic activity and proper subcellular trafficking.
presenilin-1 ([PSEN1) and presenilin-2 (PSEN2 are the catalytic cores of the gamma-secretase complex (De Strooper et al., 1998):
- Active site: Two catalytic aspartate residues (Asp257 in TM6 and Asp385 in TM7 of PSEN1 form the active site within the lipid bilayer
- Structure: Nine transmembrane domains; undergoes autocatalytic endoproteolysis into N-terminal fragment (NTF) and C-terminal fragment (CTF) that remain associated as the active heterodimer
- PSEN1: The predominant catalytic subunit; harbors >300 pathogenic mutations causing familial AD; expressed ubiquitously
- PSEN2: Less abundant; associated with rarer familial AD cases (approximately 40 known mutations); more tissue-restricted expression with higher levels in peripheral tissues
- Non-catalytic functions: Presenilin also regulates calcium homeostasis through ER leak channels, autophagy via lysosomal acidification, and synaptic function independently of gamma-secretase proteolytic activity
- Structure: Type I transmembrane glycoprotein (~130 kDa) with a large ectodomain that acts as a substrate gatekeeper
- Function: Recognizes substrates by their short ectodomain stubs (created by prior ectodomain shedding); Glu333 in the DAP domain is critical for substrate binding; substrates with ectodomains longer than ~50 amino acids are excluded
- Maturation: Extensive N-glycosylation in the Golgi is required for proper folding, trafficking, and complex assembly
- Isoforms: APH-1A (two splice variants: APH-1aS and APH-1aL) and APH-1B; different isoforms form distinct gamma-secretase complexes with different substrate preferences
- Structure: Seven transmembrane domains forming the structural backbone of the complex
- Function: Stabilizes the nascent presenilin-nicastrin interaction during early assembly in the ER
- APH-1B complexes: Recent cryo-EM studies reveal that APH-1B-containing gamma-secretase has distinct structural features at the substrate-binding site, with implications for differential Aβ processing (Yang et al., 2024)
- Structure: Small protein (~12 kDa) with hairpin-like topology containing two transmembrane segments
- Function: Triggers presenilin endoproteolysis (NTF/CTF formation), converting the immature complex into its catalytically active form; the last subunit to join during sequential complex assembly
- Regulation: PEN-2 binding is the rate-limiting step in gamma-secretase maturation
The structure of human gamma-secretase was first resolved by cryo-EM at 3.4 angstrom resolution, revealing the arrangement of 19 transmembrane helices from the four subunits (Bai et al., 2015). Key structural insights include:
- Horseshoe-shaped arrangement: Transmembrane helices form a partial ring enclosing a hydrophilic cavity within the membrane
- Flexible active site: TM2 and TM6 of presenilin exhibit considerable conformational plasticity, enabling the enzyme to accommodate substrates of different sizes and sequences
- Water-accessible channel: The active site aspartates are positioned within a water-filled cavity that enables hydrolysis within the lipid bilayer
- Substrate entrance: A lateral gate between TM2 and TM6 of presenilin allows substrate access from the lipid membrane
Recent cryo-EM structures of gamma-secretase bound to APP-C99 substrate and Abeta intermediates have provided unprecedented mechanistic insights (Chen et al., 2024):
- The substrate transmembrane helix is unwound within the active site, forming a beta-strand that creates a hybrid beta-sheet with presenilin residues
- Fit-Stay-Trim model: Substrate initially binds (Fit), is retained by the hybrid beta-sheet (Stay), and is sequentially trimmed by processive cleavage (Trim)
- Sliding-Unwinding mechanism: The substrate helix progressively unwinds and slides through the active site during each tripeptide cleavage cycle
- Tilting-Unwinding mechanism: An alternative model where the substrate tilts relative to the active site between successive cleavages
- These structures explain why FAD mutations that destabilize the enzyme-substrate interaction lead to premature release of longer, more pathogenic Abeta species
¶ Lipid Environment and Membrane Dynamics
Gamma-secretase activity is profoundly influenced by the lipid composition of its membrane environment:
- Cholesterol: Essential for gamma-secretase activity; modulates the lateral pressure profile of the membrane and directly interacts with transmembrane helices of the complex
- Sphingolipids: Enriched in lipid rafts where gamma-secretase is concentrated; GM1 ganglioside promotes amyloidogenic processing
- Phospholipid acyl chain length: Longer acyl chains favor Abeta42 production; shorter chains favor Abeta40
- Brain [cholesterol metabolism]: CYP46A1 (cholesterol 24-hydroxylase) modulates membrane cholesterol and indirectly affects gamma-secretase cleavage profiles
Gamma-secretase cleaves APP-CTF (C99, generated by prior BACE1. Two major product lines exist:
Product line 1 (major, ~80–90% of Abeta):
Epsilon-cleavage at Abeta49 → Abeta46 → Abeta43 → Abeta40
Product line 2 (~10–20% of Abeta):
Epsilon-cleavage at Abeta48 → Abeta45 → Abeta42 → Abeta38
Each successive tripeptide cleavage releases a short peptide (initially AICD + Abeta49/48, then sequential trimming in 3-residue increments). The ratio of Abeta42 to Abeta40 is a critical determinant of amyloid pathogenicity:
- Normal: Abeta40 accounts for ~80–90% of total Abeta; Abeta42 is ~5–10%
- FAD mutations: Shift processing toward longer, more aggregation-prone species (Abeta42, Abeta43) by reducing processivity
Gamma-secretase cleaves >150 type I transmembrane substrates after ectodomain shedding. Key substrates include:
| Substrate |
Shedding Enzyme |
Biological Significance |
| APP |
[BACE1 |
Generates Abeta; central to AD pathogenesis |
| Notch1–4 |
ADAM10/TACE |
Cell fate determination, T/B cell maturation, angiogenesis |
| N-cadherin |
ADAM10 |
Cell adhesion, synaptic plasticity |
| ErbB4 |
ADAM17/TACE |
Neuregulin signaling, neural development |
| E-cadherin |
MMP-7 |
Epithelial cell adhesion |
| CD44 |
MMP-14 |
Cell migration, immune function |
| LRP1 |
Various MMPs |
Lipoprotein metabolism, Abeta clearance |
| TREM2 |
ADAM10/17 |
Microglial activation (generates sTREM2) |
| p75(NTR) |
ADAM17 |
Neurotrophin signaling, apoptosis |
The broad substrate repertoire explains why complete inhibition of gamma-secretase is not therapeutically viable — Notch signaling disruption alone produces severe on-target toxicities.
¶ Presenilin Mutations and Familial AD
Over 300 pathogenic PSEN1 mutations and approximately 40 PSEN2 mutations cause autosomal dominant early-onset AD (familial AD, FAD) (Sun et al., 2017; Szaruga et al., 2017):
- Most mutations reduce gamma-secretase processivity (the trimming function), leading to premature substrate release and increased production of longer, more aggregation-prone Abeta species (Abeta42, Abeta43)
- The Abeta42/Abeta40 ratio — not total Abeta production — is the primary pathogenic parameter
- Some mutations reduce overall gamma-secretase activity while others selectively impair trimming without affecting initial cleavage
- Cryo-EM studies show that FAD mutations destabilize the enzyme-substrate hybrid beta-sheet, leading to earlier substrate release before trimming is complete
- PSEN1: Onset typically 30–60 years; autosomal dominant with near-complete penetrance; associated with aggressive disease course; some mutations cause spastic paraparesis or cerebellar ataxia in addition to dementia
- PSEN2: Onset typically 40–75 years; reduced penetrance compared to PSEN1; variable phenotypic expression even within families
- [DIAN] studies: The Dominantly Inherited Alzheimer Network enables presymptomatic study of mutation carriers, revealing biomarker changes beginning 15–20 years before symptom onset, including declining Abeta42/40 ratio in CSF, rising amyloid PET signal, and emerging tau] pathology
| Mutation |
Onset Age |
Special Features |
| A246E |
~55 years |
Common in Colombian kindred |
| E280A (Paisa) |
~44 years |
World's largest FAD kindred (Antioquia, Colombia); DIAN-TU trial target |
| L166P |
~24 years |
One of the youngest onset ages; nearly eliminates processivity |
| A431E |
~40 years |
Common in Mexican-American families |
| H163R |
~50 years |
Common in Northern European populations |
| N141I (PSEN2) |
~55 years |
Volga German kindred; variable penetrance |
First-generation GSIs aimed to reduce Abeta production by blocking the active site but failed due to on-target Notch inhibition toxicity:
| Compound |
Developer |
Outcome |
Key Issue |
| Semagacestat (LY450139) |
Eli Lilly |
Failed Phase III (2010) |
Worsened cognition; severe Notch-related toxicity |
| Avagacestat (BMS-708163) |
BMS |
Failed Phase II |
Notch-related side effects; poor selectivity |
| MK-0752 |
Merck |
Oncology trials only |
Dose-limiting GI toxicity from Notch inhibition |
Toxicities included gastrointestinal dysfunction (goblet cell metaplasia), immune suppression (impaired T/B cell maturation), skin abnormalities (squamous cell carcinoma risk), and paradoxical cognitive worsening (possibly from Abeta rebound, loss of AICD signaling, or disruption of other substrate processing).
GSMs represent a more refined approach: they shift gamma-secretase cleavage patterns without blocking the active site, reducing Abeta42/43 production while increasing shorter, less pathogenic Abeta38/37 species (Wolfe, 2019):
First-generation (NSAID-derived) GSMs:
- Some NSAIDs (sulindac sulfide, ibuprofen, flurbiprofen) showed weak GSM activity through COX-independent mechanisms
- Tarenflurbil (R-flurbiprofen) failed Phase III due to insufficient CNS penetration and low potency
- Demonstrated proof-of-concept that modulation is pharmacologically feasible
Second-generation GSMs:
- E2012 (Eisai): Potent imidazole-based GSM; development paused due to lenticular opacity in preclinical studies
- BPN-15606: Potent, brain-penetrant GSM showing robust Abeta42 reduction in preclinical models
- RG6289 (Roche): Highly potent GSM (<10 nM IC50) with no effect on Notch or other substrate processing; reduces Abeta42 and Abeta40 while proportionally increasing Abeta38 and Abeta37; Phase I pharmacokinetic and biomarker study completed in 2023–2024 in 24 PSEN1 E280A mutation carriers from the Colombian kindred
- GSM-1 and related compounds: Research tools that have advanced understanding of allosteric modulation sites
Mechanism of GSMs:
GSMs bind to the substrate-enzyme interface and allosteric sites on presenilin/APP, enhancing processivity without occluding the active site. This increases the number of tripeptide cleavage cycles, converting more Abeta42 → Abeta38 and Abeta40 → Abeta37 without affecting Notch cleavage. Cryo-EM and photoaffinity labeling studies have identified GSM binding sites near the interface of TM1 and TM7 of presenilin.
An alternative strategy is to selectively inhibit APP cleavage while sparing Notch and other substrates:
- Substrate-specific GSIs: Compounds that exploit structural differences between APP-C99 and Notch transmembrane domains
- Presenilin conformation correctors: Small molecules that restore normal processivity to mutant presenilin, specifically targeting the FAD-associated processivity defect
- APP-binding compounds: Agents that modulate the conformation of APP-C99 to favor shorter Abeta species
¶ Current Therapeutic Landscape
Given the challenges of direct gamma-secretase targeting, the field has diversified:
- Anti-Abeta immunotherapy: lecanemab and donanemab (FDA-approved) target Abeta directly, bypassing secretase modulation
- [BACE1 inhibitors: Reduce Abeta production upstream; clinical trials discontinued due to cognitive side effects (verubecestat, atabecestat, elenbecestat, umibecestat)
- Gene therapy: CRISPR-based approaches to correct specific PSEN1 mutations in familial AD
- Combination strategies: The DIAN-TU LEAD trial is testing lecanemab + E2814 (anti-MTBR-tau] antibody) in presenilin mutation carriers
Presenilin has gamma-secretase-independent functions with significant implications for neurodegeneration:
- ER calcium regulation: Presenilin forms calcium leak channels in the endoplasmic reticulum; FAD mutations impair this function, leading to ER calcium overload and dysregulated calcium signaling. This may contribute to synaptic dysfunction and neuronal vulnerability independently of Abeta
- autophagy and lysosomal function: Presenilin facilitates lysosomal acidification by promoting v-ATPase assembly and trafficking to lysosomes; loss-of-function mutations impair autophagy-lysosomal degradation, leading to accumulation of autophagic vacuoles observed in dystrophic neurites
- Wnt/beta-catenin signaling: Presenilin interacts with beta-catenin at cell-cell junctions, modulating cell adhesion and Wnt signaling; disruption contributes to synaptic instability
- Synaptic function: Presenilin regulates neurotransmitter release, synaptic vesicle trafficking, and long-term potentiation (LTP through mechanisms involving calcium and NMDA receptor] receptor modulation
GSAP selectively enhances APP processing by gamma-secretase without affecting Notch cleavage. GSAP interacts with the gamma-secretase-APP-C99 complex and promotes Abeta production. Imatinib (a kinase inhibitor) reduces GSAP levels and Abeta production, suggesting GSAP as an alternative therapeutic target.
Gamma-secretase resides in multiple cellular compartments with different functional consequences:
- ER/Golgi: Site of complex assembly and maturation; some Abeta generation occurs here
- Plasma membrane: Active complexes generate Abeta at the cell surface
- Endosomes/lysosomes: Major site of Abeta production; acidic pH enhances activity
- Lipid rafts: Cholesterol- and sphingolipid-enriched microdomains concentrate gamma-secretase and APP, promoting amyloidogenic processing
¶ Transcriptional and Post-Translational Regulation
- Presenilin expression is regulated by ERG1, SP1, and NF-κB transcription factors
- Phosphorylation of presenilin (by CK1, CK2, GSK-3beta, PKA) modulates activity and protein interactions
- Ubiquitination targets presenilin for proteasomal degradation
- Palmitoylation affects subcellular trafficking
The study of Gamma Secretase Complex has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [De Strooper B. [Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex]https://pubmed.ncbi.nlm.nih.gov/12546056/)
- De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of [presenilin-1 inhibits the normal cleavage of amyloid precursor proteinhttps://pubmed.ncbi.nlm.nih.gov/10639274/]. Nature. 1998;391(6665):387-390.
- [Bai XC, Yan C, Yang G, et al. [An atomic structure of human gamma-secretase]https://pubmed.ncbi.nlm.nih.gov/25854361/)
- [Wolfe MS. [Dysfunctional gamma-secretase in familial Alzheimer's Disease]https://pubmed.ncbi.nlm.nih.gov/31058694/)
- [Yang G, Zhou R, Guo Q, et al. [Apo and Abeta46-bound gamma-secretase structures provide insights into amyloid processing by the APH-1B isoform]https://www.nature.com/articles/s41467-024-48776-2)
- [Chen F, Bhatt S, Yang G. [Emerging structures and dynamic mechanisms of gamma-secretase for Alzheimer's Disease]https://pubmed.ncbi.nlm.nih.gov/38767485/)
- [Takasugi N, Tomita T, Hayashi I, et al. [The role of presenilin cofactors in the gamma-secretase complex]https://pubmed.ncbi.nlm.nih.gov/12660785/)
- [Szaruga M, Munteanu B, Lismont S, et al. [Alzheimer's-causing mutations shift Abeta length by destabilizing gamma-secretase-Abeta interactions]https://pubmed.ncbi.nlm.nih.gov/28753424/)
- [Zhou R, Yang G, Guo X, et al. [Recognition of the amyloid precursor protein by human gamma-secretase]https://pubmed.ncbi.nlm.nih.gov/30630874/)
- [Sun L, Zhou R, Yang G, et al. [Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Abeta42 and Abeta40 peptides by gamma-secretase]https://pubmed.ncbi.nlm.nih.gov/27930341/)
- [Bhatt S, Bhatt MS, et al. [The gamma-secretase complex: from basic research to pharmacological intervention]https://pubmed.ncbi.nlm.nih.gov/24310227/)
- [Bhatt S, et al. [Gamma-secretase: once and future drug target for Alzheimer's Disease]https://www.tandfonline.com/doi/full/10.1080/17460441.2023.2277350)
- [Bhatt S, et al. [Gamma-secretase targeting in Alzheimer's Disease]https://pmc.ncbi.nlm.nih.gov/articles/PMC12188074/)
- [Bhatt S, Bhatt DL, et al. [New precision medicine avenues to the prevention of Alzheimer's Disease from insights into the structure and function of gamma-secretases]https://link.springer.com/article/10.1038/s44318-024-00057-w)